Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Heart Matters

SELECT Trial: Semaglutide Lowers CVD Risk in Patients with Obesity

ReachMD Healthcare Image
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Comments
  • Overview

    Findings from the SELECT trial show that GLP-1 agonist, semaglutide, had significant reduction in major adverse cardiovascular disease events for overweight or obese patients without a prior history of diabetes. Read more to learn about the findings and its impact on these patients.

Recommended
Details
Comments
  • Overview

    Findings from the SELECT trial show that GLP-1 agonist, semaglutide, had significant reduction in major adverse cardiovascular disease events for overweight or obese patients without a prior history of diabetes. Read more to learn about the findings and its impact on these patients.

Schedule9 Oct 2024